Incyte | INCY - Ebit



金融业
股票价格
USD
资产
USD 7.34B
现金及等价物
USD 4.02B
销售成本
USD 104.5M
流动资产
USD 5.48B
流动负债
USD 1.49B
债务
USD 39.43M
EBIT
USD 344.17M
EBITDA
USD 367.97M
员工
2.62K
EPS每股收益
USD 1.81
股本和储备
USD 5.62B
销售毛利
USD 1.17B
债务利息支出
USD 569K
利息收入
USD 33.69M
贷款资金
USD 29.41M
市值
USD 21.63B
净收入
USD 303.33M
营业费用
USD 5.62B
营业利润
USD 324.17M
普通股股本
USD 199.95M
PE价格收益
15.35
税前利润
USD 343.6M
销售收入
USD 1.27B
销售和管理费用
USD 328.1M
股票
USD 115.62M
贸易债权人
USD 228.62M
应收帐款人
USD 1.05B


Ebit 更改 日
Acadia Pharmaceuticals USD -4.62M 22.01M 2026-03
Agenus USD 14.4M 19.26M 2025-12
Agios Pharmaceuticals USD -110.02M 11.55M 2026-03
Alnylam Pharmaceuticals USD 137.59M 108.19M 2026-03
Amgen USD 3.83B 130M 2026-03
BioCryst Pharmaceuticals USD 260.38M 230.79M 2025-12
Biogen USD 514.3M 502.8M 2026-03
BioMarin Pharmaceutical USD 129.65M 68.74M 2026-03
Bristol-Myers Squibb USD 3.56B 90M 2026-03
Eli Lilly USD 9.78B 792M 2026-03
Exelixis USD 251.34M 15.43M 2026-03
Gilead Sciences USD 2.68B 284M 2026-03
Incyte USD 344.17M 39.71M 2026-03
Ionis Pharmaceuticals USD -118M 97M 2026-03
MacroGenics USD -12.1M 32.26M 2025-12
Merck USD -1.88B 8.12B 2026-03
Moderna USD -1.39B 531M 2026-03
Nektar Therapeutics USD -19.09M 15.26M 2025-12
Neurocrine Biosciences USD 214.6M 13.3M 2026-03
Novartis USD 4.18B 118M 2026-03
Novartis USD 4.06B 413M 2025-12
Pfizer USD 4.99B 340M 2026-03
PTC Therapeutics USD 45.89M 127.51M 2026-03
Puma Biotechnology USD -2.2M 11.41M 2024-06
Regeneron Pharmaceuticals USD 744.8M 153.8M 2026-03
Sarepta Therapeutics USD 358.43M 768.52M 2026-03
Ultragenyx Pharmaceutical USD -216M 102M 2026-03
Vertex Pharmaceuticals USD 1.14B 124.5M 2026-03